ArticleNutrients2022

Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.

Sara Volpe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.